Literature DB >> 3552320

Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency.

C Angelini, C Trevisan, G Isaya, G Pegolo, L Vergani.   

Abstract

Several clinical entities are associated with disorders of fatty acid oxidation or transfer across the inner mitochondrial membrane. Over 40 cases of the primary carnitine deficiency syndrome have been reported to date and various subtypes have been characterized. This represents a large clinical spectrum. The deficiency of carnitine in muscle is at the basis of a syndrome characterized by muscle weakness and lipid storage myopathy. The systemic form of carnitine deficiency is more generalized and includes recurrent episodes of hepatic encephalopathy as well as lipid storage in muscle, liver and heart. In one subtype, hypoglycemia upon fasting and cardiomyopathy are found. There are also several causes of secondary carnitine deficiency states which are either acquired or associated with inborn errors of metabolism (organic acidurias, defects of acyl-CoA dehydrogenases). Clinically, Carnitine palmitoyltransferase (CPT) deficiency is a rather homogeneous syndrome presenting with recurrent episodes of myoglobinuria provoked by fasting or prolonged exercise. The only exception is an infantile variety associated with severe hypoglycemia and hepatic CPT deficiency. Using malonyl-CoA, a specific inhibitor of CPT-I, we had suggestions in five adult patients with myoglobinuria that CPT-II is lacking in muscle, liver and platelets while CPT-I is above the control level. The enzyme abnormality seems partial and limited to CPT-II or to its binding to the inner mitochondrial membrane.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552320     DOI: 10.1016/s0009-9120(87)80090-5

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Exercise-induced rhabdomyolysis and transient loss of deambulation as outset of partial carnitine palmityl transferase II deficiency.

Authors:  Donato Rigante; Giulia Bersani; Adele Compagnone; Anna Zampetti; Alessia De Nisco; Emanuela Sacco; Raffaella Marrocco
Journal:  Rheumatol Int       Date:  2009-10-25       Impact factor: 2.631

Review 2.  L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.

Authors:  Gustavo C Ferreira; Mary C McKenna
Journal:  Neurochem Res       Date:  2017-05-16       Impact factor: 3.996

Review 3.  Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?

Authors:  Sachin K Majumdar; Silvio E Inzucchi
Journal:  Endocrine       Date:  2013-01-25       Impact factor: 3.633

Review 4.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

5.  Role of carnitine in disease.

Authors:  Judith L Flanagan; Peter A Simmons; Joseph Vehige; Mark Dp Willcox; Qian Garrett
Journal:  Nutr Metab (Lond)       Date:  2010-04-16       Impact factor: 4.169

6.  Skin fibroblast carnitine uptake in secondary carnitine deficiency disorders.

Authors:  I Tein; D C De Vivo; D Ranucci; S DiMauro
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.